Professor Achim Wambach ist seit April 2016 Präsident des ZEW – Leibniz-Zentrum für Europäische Wirtschaftsforschung GmbH Mannheim.

Seit 2014 ist er Mitglied der Monopolkommission und seit 2016 deren Vorsitzender. Im September 2018 wurde er zum Ko-Vorsitzenden der Kommission „Wettbewerbsrecht 4.0“ der Bundesregierung berufen. Von 2015-2018 war Achim Wambach Mitglied des Lenkungskreises der Nationalen Plattform Elektromobilität (NPE) der Bundesregierung sowie 2017-2018 des Wissenschaftlichen Beirats zur Weiterentwicklung des Risikostrukturausgleichs beim Bundesversicherungsamt. Er gehört außerdem dem Wissenschaftlichen Beirat beim Bundesministerium für Wirtschaft und Energie an (derzeit ruhend), dessen Vorsitz er von 2012-2015 innehatte.

Achim Wambach promovierte in Physik an der Universität Oxford und erwarb danach einen Master of Science in Economics an der London School of Economics. Seine Habilitation in Volkswirtschaftslehre schloss er an der Universität München ab und war Professor für Volkswirtschaftslehre an der Universität Erlangen-Nürnberg, bevor er die Position des Direktors des Instituts für Wirtschaftspolitik (iwp) an der Universität zu Köln übernahm. Für die Amtsdauer 2017/2018 war er Vorsitzender des Vereins für Socialpolitik.

In seiner Forschung beschäftigt sich Achim Wambach unter anderem mit den Schwerpunkten Marktdesign und Wettbewerbspolitik.

Margaret Kyle (MINES ParisTech and CEPR) currently holds the Chair in Intellectual Property and Markets for Technology at MINES ParisTech. Her research concerns innovation, productivity and competition. She has a number of papers examining R&D productivity in the pharmaceutical industry, specifically the role of geographic and academic spillovers; the firm-specific and policy determinants of the diffusion of new products; generic competition; and the use of markets for technology. Recent work examines the effect of trade and IP policies on the level, location and direction of R&D investment and competition. She also works on issues of innovation and access to therapies in developing countries. Her papers have been published in various journals of economics, strategy, and health policy, including the Quarterly Journal of Economics, Review of Economics and Statistics, RAND Journal of Economics, Journal of Public Economics, Journal of Industrial Economics, Journal of Law and Economics, Antitrust Law Journal, Management Science, and Health Affairs. In 2019, she was named as one of the “40 in their 40s” notable women competition professionals.

Margaret holds a PhD in economics from the Massachusetts Institute of Technology and is an associate editor of the International Journal of Industrial Organization. She previously held positions at Carnegie Mellon University, Duke University, London Business School, and the Toulouse School of Economics, and is a visiting professor at the Kellogg School of Management, Northwestern University. She has also been a visiting scholar at the Center for the Study of Innovation and Productivity at the Federal Reserve Bank of San Francisco and at the University of Hong Kong. Margaret is currently a member of the Conseil National de Productivité in France.

Vincenzo Atella is Professor of Economics at the University of Rome “Tor Vergata” where he teaches courses of Macroeconomics and Applied Health Economics at graduate and post graduate level. He is also adjunct associate of the Center for Health Policy at Stanford University where he has been visiting professor several times.

Currently, he is Scientific Director of the Farmafactoring Foundation, President of the Italian Health Economic Association (AIES), chief economist of the Italian Association of General Practitioners (SIMG) and member and of AGENAS scientific committee. In the recent past he has been member of the International Committee of Experts advising IQWiG (the German Agency for Health Care) for setting national guidelines for Economic Evaluation and member of the Italian Committee for Drug Price appointed by the Ministry of Treasury. He also served as member of the “Strategic Evaluation Committee” of the Italian Drug Agency (AIFA), and has been consultant for the Italian Regional Agency for Health Care Services, the National Institute of Health, the WHO and the World Bank. Prof. Atella has been coordinator of a large European Research Network called TECH Europe, who received financial support by the European Science Foundation.

His most recent research activity has focused on health economics. In this field his research deals with the introduction of new technologies in the health sector, the impact of different co-payment systems on pharmaceutical decision making by physicians and on drug consumption by patients, forecasting health expenditure and with health related income inequalities. The results of this research activity have been published on several international refereed journals as well books.